Summary
ANI Pharmaceuticals Inc (ANI) formerly BioSante Pharmaceuticals, Inc. is a pharmaceutical company that develops, manufactures and markets prescription pharmaceuticals. The company’s products include fluvoxamine maleate tablets USP, opium tincture USP deodorized, propafenone hydrochloride tablets USP, etodolac capsules USP, methazolamide tablets USP, cortenema hydrocortisone retention enema, and reglan metoclopramide tablets USP. It offers contract manufacturing services for other pharmaceutical companies. ANI offers products in the form of liquids, powders, suspensions, capsules, coated tablets and non-coated tablets. The company sells its products to smaller regional distributors and chains, wholesalers and distributors, and pharmacy and retail outlets. ANI is headquartered in Baudette, Minnesota, the US.
ANI Pharmaceuticals Inc (ANIP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
ANI Pharma Acquires Inderal XL form Cranford Pharma for USD20 Million 12
ANI Pharma Acquires InnoPran XL from Holmdel Pharma for USD31 Million 12
ANI Pharma Acquires Inderal LA Assets from Cranford Pharma 13
ANI Pharma Acquires Two NDAs from Merck Sharp & Dohme for USD75 Million 14
ANI Pharma Acquires Rights to Testosterone Gel 1% from Teva Pharma 15
ANI Pharma Acquires ANDA from Teva Pharma 16
ANI Pharma Acquires Vancocin Capsules and Vancomycin Assets from Shire for USD11 Million 17
ANI Pharma Acquires Lithobid from Noven Therapeutics for USD12 Million 18
ANI Pharma Acquires 22 Generic Drug Products from Teva Pharma 19
Partnerships 20
ANI Pharma Enters into Distribution Agreement with Aspen 20
ANI Pharma Enters into Agreement with H2-Pharma 21
ANI Pharma Enters into Agreement with IDT Australia 22
ANI Pharma Extends Co-Development Agreement With Sterling Pharma 22
ANI Pharma Enters Into Development Agreement With Sterling Pharma 23
Ani Pharma Enters Into Co-Development Agreement With Sofgen Pharma For Oral Soft Gel Prescription Product 24
ANI Pharma Enters into Agreement with RiconPharma 25
Merger 25
BioSante Pharma And Ani Pharma Complete Merger 25
Licensing Agreements 27
ANI Pharma Enters into Licensing Agreement with Dexcel Pharma 27
Ani Pharma Enters Into Licensing Agreement With Sofgen Pharma For Oral Soft Gel Product 28
Equity Offering 28
ANI Pharma Completes Public Offering Of Shares For US$50 Million 28
Debt Offering 29
ANI Pharma Raises USD143.8 Million in Public Offering of 3% Notes Due 2019 29
ANI Pharmaceuticals Inc - Key Competitors 32
Key Employees 33
Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35
List of Tables
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 1
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
ANI Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
ANI Pharma Acquires Inderal XL form Cranford Pharma for USD20 Million 12
ANI Pharma Acquires InnoPran XL from Holmdel Pharma for USD31 Million 12
ANI Pharma Acquires Inderal LA Assets from Cranford Pharma 13
ANI Pharma Acquires Two NDAs from Merck Sharp & Dohme for USD75 Million 14
ANI Pharma Acquires Rights to Testosterone Gel 1% from Teva Pharma 15
ANI Pharma Acquires ANDA from Teva Pharma 16
ANI Pharma Acquires Vancocin Capsules and Vancomycin Assets from Shire for USD11 Million 17
ANI Pharma Acquires Lithobid from Noven Therapeutics for USD12 Million 18
ANI Pharma Acquires 22 Generic Drug Products from Teva Pharma 19
ANI Pharma Enters into Distribution Agreement with Aspen 20
ANI Pharma Enters into Agreement with H2-Pharma 21
ANI Pharma Enters into Agreement with IDT Australia 22
ANI Pharma Extends Co-Development Agreement With Sterling Pharma 22
ANI Pharma Enters Into Development Agreement With Sterling Pharma 23
Ani Pharma Enters Into Co-Development Agreement With Sofgen Pharma For Oral Soft Gel Prescription Product 24
ANI Pharma Enters into Agreement with RiconPharma 25
BioSante Pharma And Ani Pharma Complete Merger 25
ANI Pharma Enters into Licensing Agreement with Dexcel Pharma 27
Ani Pharma Enters Into Licensing Agreement With Sofgen Pharma For Oral Soft Gel Product 28
ANI Pharma Completes Public Offering Of Shares For US$50 Million 28
ANI Pharma Raises USD143.8 Million in Public Offering of 3% Notes Due 2019 29
ANI Pharmaceuticals Inc, Key Competitors 32
ANI Pharmaceuticals Inc, Key Employees 33
ANI Pharmaceuticals Inc, Other Locations 34
ANI Pharmaceuticals Inc, Subsidiaries 34
List of Figures
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
